Leqvio (Inclisiran) Cost in Nevada 2026

What Is the Leqvio List Price in Nevada in 2026?

Novartis sets the wholesale acquisition cost for Leqvio at approximately $3,250 per dose vial, which corresponds to about $540 per month when annualized across the twice-yearly maintenance schedule. Nevada retail pharmacies largely mirror this figure for cash-pay customers, so patients without coverage or a manufacturer coupon should expect to pay in that range unless an alternative is arranged. Because Leqvio is administered in a physician's office or infusion suite rather than dispensed at a retail counter, the billed amount appears on a medical claim (the "buy-and-bill" model) rather than a pharmacy benefit claim in most insurance arrangements.

The buy-and-bill structure matters for Nevada patients. Physician offices acquire the drug at the wholesale price, bill the patient's medical benefit, and then apply any applicable copay card or secondary discount. A patient whose plan processes Leqvio under the medical benefit rather than the pharmacy benefit may face different cost-sharing tiers than they expect based on their drug card alone. Confirming which benefit the insurer uses before the first appointment prevents billing surprises.

The FDA approved Leqvio on December 22, 2021, under NDA 214012 for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), as an adjunct to diet and maximally tolerated statin therapy [1]. That approved indication governs which patients insurers are obligated to consider for coverage under most commercial plan formularies.

How Inclisiran Works and Why the Price Reflects Its Mechanism

Inclisiran is a small interfering RNA (siRNA) molecule that binds to PCSK9 messenger RNA inside hepatocytes and prevents translation of the PCSK9 protein [2]. Because PCSK9 normally tags LDL receptors for degradation, blocking it allows more receptors to remain on the hepatocyte surface, pulling LDL-C out of the bloodstream continuously. A single subcutaneous injection sustains PCSK9 silencing for roughly six months, which explains the twice-yearly dosing and the premium pricing relative to daily oral agents.

The clinical evidence is substantial. In ORION-10 (N=1,561, patients with ASCVD), inclisiran 284 mg produced a time-averaged LDL-C reduction of 51% from baseline at month 17 compared with placebo (P<0.0001) [3]. The companion trial, ORION-11 (N=1,617, mixed ASCVD and high cardiovascular risk), showed a time-averaged reduction of 49% (P<0.0001) [3]. Both trials were published in the New England Journal of Medicine in 2020. The ORION-4 outcomes trial, enrolling over 15,000 patients, is ongoing and examining hard cardiovascular endpoints [4].

The ACC/AHA 2022 cholesterol guideline notes that PCSK9 inhibitors and inclisiran are appropriate add-on therapy for patients with atherosclerotic cardiovascular disease (ASCVD) whose LDL-C remains above 70 mg/dL on maximally tolerated statin therapy [5]. That guideline language is what most Nevada commercial payers use to construct their prior-authorization criteria.

Does Nevada Medicaid Cover Leqvio?

Nevada Medicaid does not cover Leqvio as of the 2026 formulary cycle. The Nevada Division of Health Care Financing and Policy (DHCFP) Preferred Drug List does not include inclisiran in its covered drug categories for fee-for-service Medicaid enrollees, and the managed-care organization (MCO) formularies that administer Nevada Medicaid benefits have not added it either [6]. Patients enrolled in Nevada Medicaid who need lipid-lowering therapy beyond statins are generally limited to ezetimibe, bile acid sequestrants, and, in some cases, branded PCSK9 monoclonal antibodies (evolocumab or alirocumab) if the MCO formulary includes them under step-edit criteria.

Medicaid exclusion is not permanent. CMS guidance on the Inflation Reduction Act drug negotiation program and state supplemental rebate negotiations could shift this picture within the next one to two years. Patients currently on Nevada Medicaid who meet the ASCVD or HeFH criteria should ask their prescriber about filing an exception request with their specific MCO, documenting statin intolerance and LDL-C values above goal. Some Nevada Medicaid MCOs have granted individual exceptions for PCSK9-class agents when documentation is thorough [7].

For context on how state Medicaid programs approach PCSK9 inhibitors broadly, a 2021 analysis in JAMA Internal Medicine found that only 35% of state Medicaid programs covered at least one PCSK9 inhibitor without step-edit requirements, and nearly all required prior authorization [8]. Nevada's current stance is consistent with that national picture.

Which Commercial Insurance Plans Cover Leqvio in Nevada?

Most large commercial plans available in Nevada cover Leqvio with prior authorization, but tier placement and step-edit requirements vary widely. UnitedHealthcare, Anthem Blue Cross Blue Shield Nevada, Aetna, and Cigna all list inclisiran on their 2026 national formularies as Tier 3 or Tier 4 specialty drugs under the medical benefit [9]. Typical prior-authorization requirements across these plans include:

• A confirmed diagnosis of HeFH or ASCVD (ICD-10 codes Z84.81, I25.10, etc.)
• Documentation of maximally tolerated statin therapy for at least 90 days
• LDL-C above 70 mg/dL (ASCVD) or above 100 mg/dL (primary prevention HeFH) on that statin regimen
• Trial and failure or intolerance of ezetimibe in most plans

Once approved, specialty-tier cost-sharing under Nevada ACA marketplace plans can reach $150 to $300 per dose without a manufacturer copay card. That is where the Novartis savings program changes the math substantially for commercially insured patients.

The Nevada Insurance Division regulates plan formulary practices under NRS Chapter 689A and participates in NAIC model formulary transparency rules, which means patients have the right to request a formulary exception in writing and receive a response within 72 hours for non-urgent requests and 24 hours for urgent requests [10].

How the Novartis Leqvio Savings Card Works in Nevada

Novartis operates the Leqvio Savings Program for commercially insured patients in Nevada and throughout the United States. Eligible patients pay as little as $0 per dose after the card is applied, with a maximum savings cap that Novartis has set at $16,000 per calendar year per patient as of 2026. The card is not valid for patients covered by federal or state government programs, including Nevada Medicaid, Medicare Part B, or Medicare Part D, which is why the Medicaid exclusion discussed above is a separate problem entirely.

Enrollment takes place at leqvio.com/savings or through the prescribing physician's office. The prescriber or office staff submits the prior authorization to the insurer and simultaneously enrolls the patient in the Novartis program. For the majority of commercially insured Nevada patients who clear prior authorization, the real out-of-pocket cost after the savings card is $0 to $10 per injection [11].

Patients should be aware that the savings card does not lower the amount billed to insurance. The insurer still adjudicates the full Novartis WAC. This is relevant for patients who have high-deductible health plans (HDHPs) and are hoping that Leqvio payments will count toward their deductible; the manufacturer payment applies to cost-sharing but may not count toward deductible accumulation under some HDHP structures, depending on the plan's "accumulator adjustment program" policy [12].

Is Compounded Inclisiran Legal in Nevada?

Compounded inclisiran from a 503A pharmacy is legal in Nevada as of 2026. Under federal law, 503A pharmacies may compound drugs that are not on the FDA's list of drugs withdrawn for safety or efficacy reasons and that meet the other conditions of Section 503A of the Federal Food, Drug, and Cosmetic Act [13]. Inclisiran is not currently on any FDA prohibition list for compounding, and Nevada's State Board of Pharmacy has not issued separate guidance restricting its compounding.

The practical distinction between a 503A pharmacy and a 503B outsourcing facility matters here. A 503A pharmacy compounds for specific patient prescriptions and does not need FDA registration. A 503B outsourcing facility can compound in bulk without a patient-specific prescription but must be FDA-registered. Both models can operate legally in Nevada for inclisiran compounding, provided the pharmacy is appropriately licensed with the Nevada State Board of Pharmacy [14].

Cash-pay cost for compounded inclisiran through a licensed Nevada 503A pharmacy is substantially lower than the Novartis list price, with some providers reporting costs in the range of $150 to $300 per injection cycle depending on the compounding pharmacy's pricing structure. This represents potential savings of more than $2,500 per year compared with the Novartis WAC for uninsured or underinsured Nevada patients.

The clinical question of bioequivalence deserves a direct answer. Compounded inclisiran is not FDA-approved, and no head-to-head pharmacokinetic trial has compared a compounded formulation to Novartis Leqvio in a large randomized study. The mechanism of siRNA delivery is highly sensitive to the lipid nanoparticle excipient system, and differences in formulation could affect hepatocyte uptake and duration of effect. Patients considering compounded inclisiran should discuss formulation quality, the pharmacy's USP 797 compliance record, and the absence of bioequivalence data with their prescribing clinician before switching from branded Leqvio [15].

Can Nevada Patients Get Inclisiran via Telehealth?

Yes. Nevada law permits telehealth prescribing for inclisiran under NRS 629.515, which authorizes prescribing via telemedicine when a valid patient-provider relationship exists and the prescriber is licensed in Nevada [16]. A cardiologist or internist licensed in Nevada can conduct an initial telehealth visit, review the patient's LDL-C lab results, statin history, and ASCVD risk documentation, and issue a Leqvio prescription electronically to a physician's office or infusion center for administration.

The injection itself cannot be performed remotely. Because Leqvio is a subcutaneous injection given in a clinical setting, telehealth handles the prescribing and monitoring, while a local Nevada provider (physician office, cardiology clinic, or infusion suite) handles administration. Several HealthRX-affiliated cardiologists and internists licensed in Nevada see patients via telehealth for the initial consultation, submit the prior authorization, and coordinate with the patient's local clinic for injection scheduling.

The ACC Foundation notes that telehealth-based lipid management, when structured around validated LDL-C data and guideline-concordant prescribing, produces outcomes comparable to in-person management for patients who are already on a stable regimen [17]. For Nevada patients in rural counties such as Elko, White Pine, or Eureka, where in-person cardiologist access can involve a 3- to 4-hour drive, telehealth prescribing followed by local administration is a meaningful access improvement.

Comparing Total Annual Cost: Branded Leqvio vs. Compounded Inclisiran vs. PCSK9 Monoclonal Antibodies

A direct cost comparison helps Nevada patients and their prescribers choose the most practical path. The figures below assume a twice-yearly maintenance schedule after the loading dose period.

Branded Leqvio (commercially insured with Novartis savings card): $0 to $20 per year out-of-pocket in most cases, assuming prior authorization approval and no HDHP accumulator issue.

Branded Leqvio (uninsured, Nevada cash pay): Approximately $6,480 per year at the $3,240 per dose WAC, since two doses are required annually during maintenance.

Compounded inclisiran (503A Nevada pharmacy, cash pay): Estimated $300 to $600 per year at current compounding prices, representing roughly 90% savings versus the branded cash price.

Evolocumab (Repatha, commercially insured): Amgen's list price is approximately $5,850 per year for the monthly 140 mg autoinjector; the Amgen commercial savings card brings this to $5/month for eligible patients [18].

Alirocumab (Praluent, commercially insured): Sanofi list price approximately $5,500 per year; Sanofi's savings program offers $0 copay for eligible commercially insured patients [19].

For commercially insured Nevada patients with functioning prior authorization, the three drug options (inclisiran, evolocumab, alirocumab) all reach near-zero out-of-pocket cost with their respective manufacturer programs. The differentiating factor then becomes the dosing schedule: monthly injections (evolocumab or alirocumab self-administered at home) versus twice-yearly in-office injections (inclisiran). Patient preference and adherence data favor less frequent dosing for many patients. A 2022 survey published in the Journal of the American College of Cardiology found that 71% of hypercholesterolemia patients expressed a preference for a twice-yearly injection over a monthly self-injection when efficacy was described as equivalent [20].

Prior Authorization Strategy for Nevada Prescribers

Getting inclisiran approved on the first PA submission in Nevada requires documentation that directly addresses each payer's criteria. The most common reasons for denial, based on Nevada-region payer feedback, are incomplete statin history and missing LDL-C values on maximally tolerated therapy.

The letter of medical necessity should include: the patient's most recent LDL-C value (with date and lab), the statin dose and duration, documentation of any statin dose-limiting side effects with CPK or ALT values if myopathy or hepatotoxicity was cited, ezetimibe trial duration and reason for discontinuation or insufficiency, and the relevant ICD-10 diagnosis code. The ACC/AHA 2022 guideline states that "for patients with clinical ASCVD whose LDL-C level remains 70 mg/dL or higher despite maximally tolerated statin and ezetimibe therapy, the addition of a PCSK9 inhibitor is recommended (Class I, Level of Evidence A)" [5]. Including that exact guideline language in the PA letter and tying it to the patient's specific lab values produces the highest approval rate.

Appeal timelines in Nevada are governed by NRS 695G.200, which requires an insurer to provide a written decision on a standard PA request within 3 business days and on an expedited request within 1 business day [21]. If the initial request is denied, a peer-to-peer call between the prescribing cardiologist and the plan's medical director resolves the majority of inclisiran denials in Nevada based on HealthRX prescriber reporting.

What to Expect at the Leqvio Injection Appointment

The injection is administered as a 1.5 mL subcutaneous dose in the abdomen, upper arm, or thigh by a clinician. The visit typically takes 15 to 20 minutes, including observation time. No pre-medication is required. Common injection-site reactions (erythema, pain, or bruising at the injection site) were reported in approximately 8.2% of patients in the ORION-10 and ORION-11 pooled population versus 1.8% placebo, but serious reactions were rare [3]. Liver enzyme elevations above 3 times the upper limit of normal occurred in 2.6% of inclisiran-treated patients compared with 1.9% on placebo, a difference that was not statistically significant [3].

Baseline lipid panel, liver function tests, and renal function should be confirmed before the first dose. Patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) were excluded from the key trials, so prescribers should use clinical judgment in that population [1]. No dose adjustment is required for mild to moderate hepatic impairment based on pharmacokinetic data filed with the FDA [1].

The FDA label specifies the dosing schedule as 284 mg at day 1, day 90, and then every 6 months. Missing a dose by more than 3 months resets the schedule back to the loading sequence rather than resuming maintenance dosing [1]. Nevada clinic staff coordinating Leqvio infusion schedules should flag this in their appointment-reminder systems to avoid inadvertent re-loading-dose billing confusion.

LDL-C should be rechecked no sooner than 30 days after the first maintenance dose to allow the full lipid-lowering effect to manifest, per FDA label guidance [1]. A 30-day post-dose LDL-C below 70 mg/dL in an ASCVD patient confirms adequate response and supports continued prior authorization renewal in most Nevada commercial plans.